Comparative Effectiveness of Bariatric Surgery vs GLP-1 RAs in Obese T2DM Patients

Overview

This systematic review and meta-analysis compared metabolic and bariatric surgery (MBS) with GLP-1 receptor agonists (GLP-1 RAs) in obese patients with type 2 diabetes mellitus (T2DM). MBS demonstrated superior reductions in all-cause mortality and major adverse cardiac events (MACE) compared to GLP-1 RAs, though both interventions improved metabolic and cardiovascular outcomes.

Background

Obesity and T2DM are interrelated conditions that significantly increase cardiovascular risk and mortality. Major adverse cardiac events such as myocardial infarction, stroke, and ischemic heart disease are more frequent in this population due to metabolic abnormalities. Metabolic and bariatric surgery has shown sustained weight loss, improved glycemic control, and cardiovascular benefits, but carries risks of surgical complications. GLP-1 receptor agonists offer weight reduction and cardiovascular risk improvement with a different adverse event profile, primarily gastrointestinal symptoms. Direct comparative data on long-term mortality and MACE between these treatments have been limited.

Data Highlights

Key Findings

• MBS leads to greater sustained weight loss (25–35%) over 2–3 years compared to GLP-1 RAs (15–25% at 1 year).
• MBS significantly reduces all-cause mortality (HR 0.30) and MACE (HR 0.58) in obese patients with T2DM.
• GLP-1 RAs improve metabolic parameters and reduce cardiovascular mortality but with less pronounced effects than MBS.
• MBS is associated with surgical risks including micronutrient deficiencies and postoperative complications.
• GLP-1 RAs are linked to gastrointestinal adverse events and weight regain after discontinuation.
• Direct comparative evidence on long-term outcomes remains limited but favors MBS for mortality and MACE reduction.

Clinical Implications

Clinicians should consider metabolic and bariatric surgery as a highly effective intervention for obese patients with T2DM to achieve sustained weight loss and reduce mortality and cardiovascular events. GLP-1 receptor agonists remain valuable for patients who are not surgical candidates or prefer medical therapy but may offer less durable benefits. Careful patient selection and monitoring for adverse events are essential with both approaches.

Conclusion

Metabolic and bariatric surgery demonstrates superior effectiveness over GLP-1 receptor agonists in reducing mortality and major cardiac events in obese patients with type 2 diabetes. Both therapies improve metabolic outcomes, but their differing risk profiles and long-term benefits should guide individualized treatment decisions.

References

1. Various Authors/Multiple Years -- Systematic Review and Meta-Analysis on MBS vs GLP-1 RAs